Form 8-K - Current report:
SEC Accession No. 0001564590-21-058942
Filing Date
2021-12-01
Accepted
2021-12-01 16:02:47
Documents
17
Period of Report
2021-11-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xene-8k_20211124.htm   iXBRL 8-K 40617
2 EX-10.1 xene-ex101_9.htm EX-10.1 446075
3 GRAPHIC g5o301mwopis000001.jpg GRAPHIC 102361
4 GRAPHIC g5o301mwopis000003.jpg GRAPHIC 46053
5 GRAPHIC g5o301mwopis000004.jpg GRAPHIC 49419
6 GRAPHIC g5o301mwopis000002.jpg GRAPHIC 49373
  Complete submission text file 0001564590-21-058942.txt   1012027

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA xene-20211124.xsd EX-101.SCH 5701
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE xene-20211124_lab.xml EX-101.LAB 19292
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xene-20211124_pre.xml EX-101.PRE 11485
10 EXTRACTED XBRL INSTANCE DOCUMENT xene-8k_20211124_htm.xml XML 3530
Mailing Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W
Business Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W (604) 484-3300
Xenon Pharmaceuticals Inc. (Filer) CIK: 0001582313 (see all company filings)

EIN.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36687 | Film No.: 211462880
SIC: 2834 Pharmaceutical Preparations